share_log

HC Wainwright & Co. Reiterates Buy on Coherus BioSciences, Maintains $13 Price Target

Benzinga ·  Dec 27, 2023 06:06

HC Wainwright & Co. analyst Douglas Tsao reiterates Coherus BioSciences (NASDAQ:CHRS) with a Buy and maintains $13 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment